SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Zonagen (zona) - good buy?
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jacques Chitte who wrote (3070)3/26/1998 2:43:00 PM
From: Linda Kaplan  Read Replies (2) of 7041
 
Alex,

Your position makes the most sense to me. Even if the FDA were to approve, by then the market will have been well saturated, and divided between Viagra and Muse. Vasomax will only be likely to be tried by the people who failed with both other drugs. Of those failures with both Viagra and Muse, I'd guess a tiny percentage will take to Vasomax. I just don't think there's that much earning potential down the road. If people find a drug that works for them of this nature, they'll stick with it, so I don't see there being much left of the market by the time Vasomax is approved, if it ever is approved.

I don't know if anyone has a grasp on the specificity -- for what conditions would Vasomax actually work, for what conditions the others would work? There's controversy about the size of the market but there can't be much controversy about the fact that Muse and Viagra will have saturated that market long before Vasomax can be approved.

Linda
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News